Clinical meaning
Gastric acid secretion is the final product of a complex signaling cascade in gastric parietal cells, and understanding this physiology is essential for rational acid suppression therapy. Parietal cells in the gastric fundus and body secrete hydrochloric acid (HCl) via the hydrogen-potassium ATPase (H+/K+-ATPase, the proton pump) located on their apical (luminal) surface. Three primary stimuli activate parietal cells: acetylcholine (vagal parasympathetic stimulation via M3 muscarinic receptors), gastrin (released from G-cells in the antrum in response to meal-related gastric distension and protein), and histamine (released from enterochromaffin-like cells and binding to H2 receptors on parietal cells). Histamine is the final common paracrine mediator — gastrin and acetylcholine both stimulate histamine release from ECL cells, making the H2 receptor a convergence point for acid secretion stimulation. Proton pump inhibitors (PPIs) irreversibly bind to the active (acid-secreting) conformation of the H+/K+-ATPase, blocking the final common pathway of acid secretion regardless of the upstream stimulus. Because PPIs only inhibit actively secreting pumps, they must be taken 30-60 minutes before a meal when meal anticipation stimulates pump translocation to the apical membrane. Since proton pumps are irreversibly inactivated, acid secretion only resumes after new pump proteins are synthesized (half-life ~54 hours), which is why PPIs achieve >90% acid suppression with once-daily dosing. H2 receptor antagonists (famotidine, ranitidine) competitively block histamine at the H2 receptor, reducing basal and nocturnal acid secretion by approximately 70% but leaving acetylcholine- and gastrin-stimulated secretion partially intact, making them less potent than PPIs. Importantly, H2 blockers develop tachyphylaxis (tolerance) within 2-6 weeks of continuous use due to upregulation of H2 receptors and alternative secretory pathways, limiting their effectiveness as chronic therapy. Chronic PPI use has several pathophysiological consequences: suppressed acid reduces calcium carbonate absorption (requiring calcium citrate for supplementation), impairs iron and vitamin B12 absorption (acid is needed to release these from food), alters gut microbiome composition (increasing Clostridioides difficile colonization risk), and triggers reactive hypergastrinemia that causes rebound acid hypersecretion upon PPI discontinuation.